Clinical Research Directory
Browse clinical research sites, groups, and studies.
Qingre Huatan Formula for the Prevention of Early Neurological Deterioration in Acute Ischemic Stroke
Sponsor: Dongzhimen Hospital, Beijing
Summary
The purpose of this study is to assess the effectiveness and safety of Qingre Huatan formula versus placebo on preventing early neurological deterioration in patients with acute ischemic stroke within 48 hours after onset.
Official title: Efficacy and Safety of Qingre Huatan Formula for the Prevention of Early Neurological Deterioration in Patients With Acute Ischemic Stroke : A Randomized Double-blind Placebo-controlled Pilot Trial
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
72
Start Date
2025-06-13
Completion Date
2026-10-29
Last Updated
2025-12-01
Healthy Volunteers
No
Conditions
Interventions
Qingre Huatan Formula
Qingre Huatan Formula, granules, 1 bag each time, twice a day, orally, continue for 10 days.
Qingre Huatan Formula placebo
Qingre Huatan Formula placebo, granules, 1 bag each time, twice a day, orally, continue for 10 days.
Guidelines-based standard care
Guidelines-based standard care for acute ischemic stroke
Locations (1)
Dongzhimen Hospital
Beijing, Beijing Municipality, China